CN Patent

CN113677336B — 包含式(i)化合物和glp-1受体激动剂的组合疗法

Assigned to Genfit SA · Expires 2024-04-30 · 2y expired

What this patent protects

本发明涉及包含PPAR激动剂和GLP‑1受体激动剂的组合疗法。

USPTO Abstract

本发明涉及包含PPAR激动剂和GLP‑1受体激动剂的组合疗法。

Drugs covered by this patent

Patent Metadata

Patent number
CN113677336B
Jurisdiction
CN
Classification
—
Expires
2024-04-30
Drug substance claim
No
Drug product claim
No
Assignee
Genfit SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.